Cefpiramide
A third-generation parenteral cephalosporin antibiotic with broad-spectrum gram-negative activity including Pseudomonas aeruginosa, used mainly in Japan and China for serious bacterial infections. Like cefoperazone, it is primarily eliminated in bile, which is advantageous in patients with renal impairment. It contains the N-methylthiotetrazole group with associated risks.
Masse moléculaire
612,6000 g/mol
LogP
-0,10
TPSA
259,00 Ų
Règle des 5 de Lipinski
Non conforme
Mécanisme d'action
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1
InChI
InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
Molecular Formula
C25H24N8O7S2
HBD / HBA
5 / 13
Liaisons Rotatives
9
Atomes Lourds
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A third-generation parenteral cephalosporin antibiotic with broad-spectrum gram-negative activity including Pseudomonas aeruginosa, used mainly in Japan and China for serious bacterial infections. Like cefoperazone, it is primarily eliminated in bile, which is advantageous in patients with renal impairment. It contains the N-methylthiotetrazole group with associated risks.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefpiramide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201204. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 636405. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefpiramide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefpiramide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefpiramide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefpiramide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefpiramide"></drugfyi-drug>